A Gharbharan, CCE Jordans… - Nature …, 2021 - nature.com
… Convalescent plasma is safe, does not improve survival, has … respiratory tract, influence SARS-CoV-2 antibody development or … of patients already had potent neutralizing SARS-CoV-2 …
… In another analysis of the dynamics of neutralizing antibody titers in eight convalescent patients with COVID-19, four patients showed decreased neutralizing antibodies approximately 6…
… SARS-CoV-2 VOCs, sera were collected from patients with … In summary, using convalescent sera from individuals infected … Infection with B.1.1.7, B.1.351 or B.1.617.2 generates a cross-…
N Sherina, A Piralla, L Du, H Wan, M Kumagai-Braesch… - Med, 2021 - cell.com
… of vaccines against this emerging virus. In this study, we aimed to assess the dynamics and longevity of the SARS-CoV-2-specific immune responses in COVID-19patients with a broad …
L Ni, F Ye, ML Cheng, Y Feng, YQ Deng, H Zhao… - Immunity, 2020 - cell.com
… to SARS-CoV-2infection. Here, we collected blood from COVID-19patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific …
HC Sullivan, JD Roback - Transfusion medicine reviews, 2020 - Elsevier
… Could plasma collected from COVID-19convalescentpatients be efficacious in treating patients still battling the infection, or as a prophylactic approach to prevent this disease? In this …
H Harvala, J Mehew, ML Robb, S Ijaz, S Dicks… - …, 2020 - eurosurveillance.org
… % on days 31–40 post symptom onset to 28% on days 41–53 [12], and decreasing neutralising antibody levels have also been noted in SARS-CoV-2infected hospitalised patients [17]. …
MR Neeland, S Bannister, V Clifford, K Dohle… - Nature …, 2021 - nature.com
… - positive individuals were non-hospitalised patients who had a positive PCR test for SARS-CoV-2 on nasopharyngeal swab and experienced mild symptoms (Table 1), including coryza…
JH Jung, MS Rha, M Sa, HK Choi, JH Jeon… - Nature …, 2021 - nature.com
… Therefore, in the present study, we could not distinguish de novo primed T cells by SARS-CoV-2 infection from pre-existing, cross-reactive ccCoV-specific T cells. However, we could …